Mvasi is approved to treat patients with certain colorectal, lung, brain, kidney and cervical cancers in combination with other therapies.
Mvasi is the first biosimilar approved by the FDA to treat cancer and represents one of four oncology bisomilars Amgen and Allergan are co-developing.
More articles on supply chain:
Teva to sell contraceptive device business for $1.1B, divest remaining women’s health assets
FDA reapproves leukemia drug 7 years after pulled from market
Supply chain inefficiencies leave $23B in potential savings on the table for hospitals
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
